# Oral Risperidone Versus Injectable Paliperidone Palmitate for Treating First-Episode Schizophrenia

> **NCT01451736** · PHASE4 · COMPLETED · sponsor: **University of California, Los Angeles** · enrollment: 146 (actual)

## Conditions studied

- Schizophrenia (Recent-onset)

## Interventions

- **DRUG:** paliperidone palmitate
- **DRUG:** risperidone

## Key facts

- **NCT ID:** NCT01451736
- **Lead sponsor:** University of California, Los Angeles
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10
- **Primary completion:** 2021-12-01
- **Final completion:** 2021-12-31
- **Target enrollment:** 146 (ACTUAL)
- **Last updated:** 2022-04-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01451736

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01451736, "Oral Risperidone Versus Injectable Paliperidone Palmitate for Treating First-Episode Schizophrenia". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01451736. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*